Stevens-johnson syndrome and toxic epidermal necrolysis standard reporting and evaluation guidelines by Maverakis, Emanual et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
Stevens-johnson syndrome and toxic epidermal necrolysis standard reporting
and evaluation guidelines
Maverakis, Emanual; Wang, Elizabeth A; Shinkai, Kanade; Mahasirimongkol, Surakameth; Margolis,
David J; Avigan, Mark; Chung, Wen-Hung; Goldman, Jennifer; La Grenade, Lois; Pirmohamed, Munir;
Shear, Neil H; Tassaneeyakul, Wichittra; Hoetzenecker, Wolfram; Klaewsongkram, Jettanong;
Rerkpattanapipat, Ticha; Manuyakorn, Wiparat; Yasuda, Sally Usdin; Sharon, Victoria R; Sukhov,
Andrea; Micheletti, Robert; Struewing, Jeff; French, Lars E; Cheng, Michelle Y
Abstract: Importance: Toxic epidermal necrolysis (TEN) and Stevens-Johnson Syndrome (SJS) are rare,
acute, life-threatening dermatologic disorders involving the skin and mucous membranes. Research into
these conditions is hampered by a lack of standardization of case reporting and data collection. Objective:
To establish a standardized case report form to facilitate comparisons and maintain data quality based on
an international panel of SJS/TEN experts who performed a Delphi consensus-building exercise. Evidence
Review: The elements presented for committee scrutiny were adapted from previous case report forms and
from PubMed literature searches of highly cited manuscripts pertaining to SJS/TEN. The expert opinions
and experience of the members of the consensus group were included in the discussion. Findings: Overall,
21 out of 29 experts who were invited to participate in the online Delphi exercise agreed to participate.
Surveys at each stage were administered via an online survery software tool. For the first 2 Delphi rounds,
results were analyzed using the Interpercentile Range Adjusted for Symmetry method and statements
that passed consensus formulated a new case report form. For the third Delphi round, the case report
form was presented to the committee, who agreed that it was ”appropriate and useful” for documenting
cases of SJS/TEN, making it more reliable and valuable for future research endeavors. Conclusions
and Relevance: With the consensus of international experts, a case report form for SJS/TEN has been
created to help standardize the collection of patient information in future studies and the documentation
of individual cases.
DOI: https://doi.org/10.1001/jamadermatol.2017.0160
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-144140
Journal Article
Published Version
Originally published at:
Maverakis, Emanual; Wang, Elizabeth A; Shinkai, Kanade; Mahasirimongkol, Surakameth; Margolis,
David J; Avigan, Mark; Chung, Wen-Hung; Goldman, Jennifer; La Grenade, Lois; Pirmohamed, Munir;
Shear, Neil H; Tassaneeyakul, Wichittra; Hoetzenecker, Wolfram; Klaewsongkram, Jettanong; Rerkpat-
tanapipat, Ticha; Manuyakorn, Wiparat; Yasuda, Sally Usdin; Sharon, Victoria R; Sukhov, Andrea;
Micheletti, Robert; Struewing, Jeff; French, Lars E; Cheng, Michelle Y (2017). Stevens-johnson syn-
drome and toxic epidermal necrolysis standard reporting and evaluation guidelines. JAMA Dermatology,
153(6):587.
DOI: https://doi.org/10.1001/jamadermatol.2017.0160
2
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Standard Reporting and Evaluation Guidelines
Results of a National Institutes of HealthWorking Group
Emanual Maverakis, MD; Elizabeth A. Wang, BS; Kanade Shinkai, MD, PhD;
SurakamethMahasirimongkol, MD, MSc, PhD; David J. Margolis, MD, PhD; Mark Avigan, MD, CM;
Wen-Hung Chung, MD, PhD; Jennifer Goldman, MD; Lois La Grenade, MD, MPH; Munir Pirmohamed, PhD, FRCP;
Neil H. Shear, MD, FRCPC, FACP; Wichittra Tassaneeyakul, PhD; WolframHoetzenecker, MD, PhD;
Jettanong Klaewsongkram, MD; Ticha Rerkpattanapipat, MD;Wiparat Manuyakorn, MD, PhD;
Sally Usdin Yasuda, MS, PharmD; Victoria R. Sharon, MD; Andrea Sukhov, BA; Robert Micheletti, MD;
Jeff Struewing, MD, MS; Lars E. French, MD; Michelle Y. Cheng, MD
IMPORTANCE Toxic epidermal necrolysis (TEN) and Stevens-Johnson Syndrome (SJS) are
rare, acute, life-threatening dermatologic disorders involving the skin andmucous
membranes. Research into these conditions is hampered by a lack of standardization of case
reporting and data collection.
OBJECTIVE To establish a standardized case report form to facilitate comparisons and
maintain data quality based on an international panel of SJS/TEN experts who performed a
Delphi consensus-building exercise.
EVIDENCE REVIEW The elements presented for committee scrutiny were adapted from
previous case report forms and from PubMed literature searches of highly citedmanuscripts
pertaining to SJS/TEN. The expert opinions and experience of themembers of the consensus
group were included in the discussion.
FINDINGS Overall, 21 out of 29 experts who were invited to participate in the online Delphi
exercise agreed to participate. Surveys at each stage were administered via an online survery
software tool. For the first 2 Delphi rounds, results were analyzed using the Interpercentile
Range Adjusted for Symmetry method and statements that passed consensus formulated a
new case report form. For the third Delphi round, the case report formwas presented to the
committee, who agreed that it was “appropriate and useful” for documenting cases of
SJS/TEN, making it more reliable and valuable for future research endeavors.
CONCLUSIONS AND RELEVANCE With the consensus of international experts, a case report
form for SJS/TEN has been created to help standardize the collection of patient information
in future studies and the documentation of individual cases.
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T oxic epidermal necrolysis (TEN)andStevens-JohnsonSyn-drome (SJS) are acute life-threateningdermatologic disor-ders that involve theskinandmucousmembranesandarise
mostly from severe adverse drug reactions. These conditions are
characterizedbyepidermal necrosis, leading toerosionsof themu-
cousmembranes,widespreaddetachmentof theepidermis, andse-
vere constitutional symptoms.1,2 The incidence of TEN is esti-
mated at 0.4 to 1.2 cases per million person-years, while SJS is
estimatedat 1.0to6.0casespermillionperson-years.3Althoughrare,
these disorders are associated with high morbidity and mortality
even in previously healthy patients.4
SomeviewTENandSJSasvariantsof the samedisease thatdif-
fer in theextentof skindetachment,withSJSdefinedashaving less
than 10% body surface area involvement and TEN defined as in-
volvement of more than 30% of body surface area. For the pur-
poses of this discussion, the term “SJS/TEN” refers to the spec-
trum of epidermal necrolysis disorders.
More than 100 drugs have been implicated in causing
SJS/TEN.5-8While drugs are important causes of both SJS/TEN, in-
fectious etiologies (or a combination of infections and drugs) and
malignancy-related causes have also been implicated in SJS.9,10 In
fact, SJS is idiopathic in 25% to50%of cases.11 Genetic susceptibil-
ity also plays a role in SJS/TEN, as evidenced by the identification
of specific drug-associated human leukocyte antigen (HLA)
alleles.12-14 In addition, the pathophysiology of SJS/TEN is not well
established, but the release of granulysin by cytotoxic lympho-
cytes and natural killer cells is thought to play a central role.12,15 Re-
cent studies linking HLA to drug-induced SJS/TEN have also high-
lightedthe importanceofTcells.16-22Theseseminaldiscoverieswere
madepossiblebycarefullydocumentedcasesofTEN.Evenso, there
is no universally accepted standardized case report form for har-
monized international reporting of TEN, the creation of which was
one goal of this National Institutes of Health (NIH) SJS/TEN work-
ing group.
General guidelines for the diagnosis of SJS/TEN are typically
basedon themorphology andextent of the lesions in the setting of
antecedentdrugexposureor illness.Scoringsystemshavebeenused
to assess themortality risk in thesepatients, including the severity-
of-illness score of toxic epidermal necrolysis (SCORTEN) scale.23
However, due in part to the rarity of the condition, diagnostic crite-
ria have not yet been established, which contributes to the chal-
lenge of performing high-quality retrospective studies on these
patients.
For theseandother reasons, there is apaucityof valuable clinical
studies on SJS/TEN. In 2015, the NIH and the Food andDrug Admin-
istration(FDA)organizedaworkshopentitled“ResearchDirections in
Genetically-Mediated Stevens-Johnson Syndrome/Toxic Epidermal
Necrolysis” (https://www.genome.gov/27560487)thatwasattended
byaninternationalpanelofSJS/TENexperts.Toadvancethefield,one
oftheimmediatenextstepsidentifiedwascomparingandharmonizing
casereport formsandphenotypingforms.Uniformcasereport forms
standardize the collection of patient information in a clinical study,
whichplayasignificant role inmaintainingdataquality.Similarly,high-
quality standardized information is necessary to interpret individual
case reports. Hereinwepresent a validated case report formcreated
from the results of a Delphi exercise performed by an NIH Working
Group of participants from the 2014NIH/FDAWorkshop.
Methods
Panel Selection
A panel of epidermal necrolysis experts (dermatologists, pharma-
cologists, and immunologists) from 16different institutes and7dif-
ferent countries was assembled for a Delphi exercise to establish a
standardizedSJS/TENcase report form. Twenty-nine expertswere
identified from the NIH/FDA workshop and received email invita-
tions toparticipate in theDelphi consensus-buildingexercise. Seven
individuals didnot respond, 1 declined, and the remaining21 agreed
to participate (Figure).
First Round
Participantswere asked to evaluate the level of appropriateness of
62 statements in relation to SJS/TEN using a scale of 1 (extremely
inappropriate) to 9 (extremely appropriate). The elements pre-
sentedwereadapted fromprevious case report formsandPubMed
literature searchesofhighly citedmanuscriptsonSJS/TEN.They in-
cluded informationaboutpathophysiology, risk factors, patienthis-
tory, signs and symptoms, diagnosis, treatment and outcome. Par-
ticipants had the option of selecting “N/A” (not applicable) if they
did not feel that they had the necessary expertise or background
knowledge to rank a particular statement.
Surveys were administered online via SurveyMonkey and re-
sults were deidentified prior to releasing them to participants. Par-
ticipants could also submit comments to be incorporated into sub-
sequent Delphi rounds.
Statistics
Using the RAND/UCLA Appropriateness Method,24 each item was
evaluatedby the 1-to-9appropriateness rating scaleandby the level
of disagreement. Amedian appropriateness value of 1.0 to 3.4was
considered “inappropriate;” 3.5 to 6.9, “uncertain;” and 7.0 to 9.0,
“appropriate.” A disagreement index (DI) was calculated as de-
scribed in eAppendix 1 in the Supplement. ADI value greater than 1
indicated a lack of consensus among the participants in regards to
the appropriateness of the statement.
Second Round
In the second round, participants ranked new statements sug-
gestedbythepanelandrevisedversionsof thestatements that failed
the first round.
Figure. SJS/TENDelphi Exercise Participants
29 Experts in SJS/TEN were invited to participate in a Delphi consensus-
building exercise to establish a standardized case report form
8 Did not participate
7 Did not respond
1 Declined
21 Agreed
Case report form was developed
after 3 rounds of the Delphi
consensus-building exercise
Overall, 29 international experts on Stevens-Johnson syndrome and toxic
epidermal necrolysis (SJS/TEN) were invited, and 21 agreed to participate.
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Third Round
Statements that were agreed upon (DI < 1) to be “appropriate”
(median rating, 7.0) were used to develop a new set of
case report forms for SJS/TEN (eAppendix 2 in the Supplement).
A final version was presented to the panel for rating the appropri-
ateness and usefulness of the newly proposed case report
forms.
Results
Participant Responses
All21participants respondedtothe firstDelphiquestionnaire (100%
response rate), and 16 of 21 participated in the second (76% re-
sponse rate). The results of the first 2 rounds are presented in the
Table.
For the third Delphi round, a set of case report forms was cre-
ated using the approved statements and the panel “agreed”
(DI = 0.31) that the formswere “very appropriate/veryuseful” (me-
dian value, 7). The response rate for the final exercise was 71% (15
of 21 participants).
Case Report Form
After the first round of the Delphi exercise, the panel agreed on
the following items. First, SJS and TEN are a single disease with
common causes and mechanism and require epidermal detach-
ment for diagnosis. The key difference between the 2 is the
extent of epidermal detachment. Second, despite having similar
mucosal erosions, erythema multiforme major (EMM) and SJS are
2 distinct diseases with different patterns of cutaneous lesions.
Third, the most reliable method to classify EMM, SJS, and TEN is
based on the morphology and extent of epidermal detachment.
Finally, mucous membrane erosions are present in all patients
with SJS/TEN.
Clinical features such as morphology of the lesions, a positive
Nikolsky sign, and constitutional symptoms were deemed helpful
in the diagnosis of SJS/TEN. Calculating a SCORTEN was also
deemed helpful. There was agreement that all patients diagnosed
with SJS or TEN should receive urologic evaluation and inpatient
OB/GYN screening and outpatient follow-up for female patients.
All patients should also receive outpatient ophthalmology
follow-up and pulmonary follow-up if there is evidence of pulmo-
nary involvement.
The second round revealed agreements on the work-up,
management, and prevention of SJS and TEN. In particular, prior
to starting allopurinol or carbamazepine in a patient of Chinese
descent or of other genetically at-risk populations, HLA-B*58:01
and HLA-B*15:02 testing should be considered, respectively.
There was strong agreement that while patients with TEN should
be managed in a specialized intensive care unit or burn unit, there
is insufficient evidence that any specific treatment aside from
supportive care is beneficial for patients with TEN.
Using the statements that the panelists “agreed”were “appro-
priate” in regards to SJS/TEN, a new case report form was devel-
oped. For the third and final Delphi round, the committee came to
an agreement that the proposed case report form was “appropri-
ate and useful” for documenting cases of SJS/TEN, making it more
reliable and valuable for future research endeavors.
Table. Disagreement Indices for Each Proposed Item
Item
Disagreement
Indexa
Items the panel agreed were “appropriate” regarding SJS/TEN
SJS and TEN are a single disease with common causes
and mechanisms. The principal difference between SJS
and TEN is the extent of epidermal detachment, which is
limited in SJS and more widespread in TEN.
0.44
SJS and TEN are most frequently caused by drugs 0.09
SJS and TEN may be caused by infectious triggers. 0.37
SJS and TEN may be idiopathic in some cases. 0.16
Drugs discontinued more than 1 month prior to onset of
mucocutaneous physical findings are highly unlikely to
cause SJS and TEN.
0.13
Drugs administered longer than 8 weeks prior to the
onset of mucocutaneous physical findings are highly
unlikely to cause SJS and TEN.
0.65
SJS and TEN most often begin between 4 and 28 days
after culprit drug administration.
0.13
Drugs highly associated with SJS and TEN include
nevirapine, lamotrigine, carbamazepine, phenytoin,
phenobarbital, allopurinol, anti-infective sulfonamides,
oxicam-NSAIDs, and sulfasalazine.
<0.01
Valproic acid alone is not a major risk factor for the
development of SJS and TEN.
0.48
Sulfonamide-related diuretics and antidiabetics are not
major risk factors for the development of SJS and TEN
0.82
Acetaminophen (paracetamol) has a low associated risk
for the development of SJS and TEN.
0.16
β-blockers, ACE inhibitors, calcium channel blockers,
thiazide diuretics, furosemide, sulfonylurea
antidiabetics, insulin, and propionic acid NSAIDs are
probably not associated with SJS and TEN.
0.92
SCORTEN accurately predicts the risk of death in
patients with SJS and TEN.
0.22
It is helpful to calculate a SCORTEN within the first 3
days of hospitalization.
0.16
It is helpful to use the ALDEN, an algorithm used to
assess drug causality, for all patients suspected of having
SJS or TEN.
0.16
It is essential to obtain detailed information on ethnicity
in all patients suspected of having SJS or TEN.
0.68
It is essential to take a medication history in all patients
suspected of having SJS and TEN.
<0.01
It is essential to take a medical history in all patients
suspected of having SJS and TEN.
<0.01
Patients with SJS or TEN caused by a drug have a better
prognosis the earlier the causative drug is withdrawn.
0.13
SJS and TEN are often heralded by fever, sore throat,
cough, and burning eyes for 1 to 3 days.
0.19
Patients with SJS and TEN frequently experience burning
pain of their skin at the start of disease.
0.24
Characterization of lesion morphology is helpful in the
diagnosis of EMM, SJS, and TEN.
0.13
The most reliable method to classify EM, SJS, and TEN is
based on lesion morphology and extent of epidermal
detachment.
0.13
Classification of SJS and TEN should be based on percent
of epidermal detachment alone.
0.79
Classification of SJS and TEN should be based on the
nature of discrete lesions and percent of epidermal
detachment.
0.16
Documentation of body surface area of baseline skin
erythema is essential in all patients suspected of having
SJS and TEN.
0.19
A positive Nikolsky sign is helpful in the diagnosis of SJS
and TEN.
0.33
Obtaining baseline photographs of all patients suspected
of having SJS and TEN is essential.
0.65
Obtaining baseline photographs of all patients suspected
of having SJS and TEN is helpful but not essential.
0.29
(continued)
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Discussion
The goal of this Delphi exercise was to obtain a consensus of the
elements needed to be included in a SJS/TEN standardized case
report form. During each round, individuals were uniformly
encouraged to give commentary on how to improve the state-
ments or the case report form. Importantly, minority opinions
Table. Disagreement Indices for Each Proposed Item (continued)
Item
Disagreement
Indexa
Typical target lesions are not present in SJS or TEN. 0.08
In the presence of epidermal detachment, atypical target
lesions and macules with or without blisters are not
required to diagnose TEN.
0.29
Mucous membrane erosions are present in all patients
with SJS and TEN.
0.98
The epithelium of the trachea, bronchi, or
gastrointestinal tract may be involved in SJS and TEN.
<0.01
Involvement of the trachea, bronchi, or gastrointestinal
tract in SJS and TEN increases morbidity.
0.13
Epidermal detachment is required for a diagnosis of TEN. 0.05
A skin biopsy is helpful, but not required, to establish a
diagnosis of SJS and TEN.
0.19
A skin biopsy for direct immunofluorescence is helpful,
but not essential, in the evaluation of SJS and TEN
0.79
Establishment of a diagnosis of SJS and TEN by a
dermatologist is helpful but not essential.
0.19
Regardless of presenting symptoms, all female patients
diagnosed with SJS or TEN should receive OB/GYN
inpatient screening and offered outpatient follow-up.
0.71
Regardless of presenting symptoms, all patients
diagnosed with SJS/TEN should receive ophthalmology
inpatient screening and offered outpatient follow-up.
0.05
It is helpful for patients diagnosed with SJS or TEN to
receive outpatient ophthalmology follow-up regardless
of the presence of ocular symptoms.
0.29
It is helpful for all patients diagnosed with SJS or TEN to
receive urologic evaluation.
0.67
It is helpful for all patients with SJS or TEN
demonstrating evidence of pulmonary involvement to
receive outpatient pulmonary follow-up.
0.29
Mucosal lesions of SJS and TEN can heal with scar
formation and adhesions.
0.13
Late ocular complications may develop in patients with
SJS and TEN whether or not severe initial eye
involvement is noted.
0.19
Restrictive lung disease may develop in patients with SJS
and TEN after initial acute pulmonary involvement.
0.13
Esophageal strictures or adhesions may develop in
patients with SJS and TEN after initial acute esophageal
involvement.
0.29
Drugs administered 24 hours or less prior to the onset of
mucocutaneous physical findings are unlikely to cause
TEN.
0.13
Slow titration of a drug does not decrease the risk of it
causing TEN.
0.32
Patients with TEN may experience pruritus of their skin
at the start of disease.
0.26
Skin lesions of TEN usually start to re-epithelialize
within 14 days and may heal without scarring. Patients
may develop temporary postinflammatory
hyperpigmentation.
0.19
In a patient with TEN, a Nikolsky sign may be elicited on
erythematous areas of skin but may not be reliably
elicited on normal appearing skin.
<0.01
It is essential to obtain an adverse drug reaction history
(both for patient and family) in all patients suspected of
having TEN.
0.13
In patients younger than 50 years, those who develop
TEN without a suspected drug should be tested for
mycoplasma pneumoniae.
0.63
Prior to starting allopurinol in a patient of Chinese
descent, HLA-B*58:01 testing should be considered.
0.13
Prior to starting carbamazepine in a patient of Chinese
descent, HLA-B*15:02 testing should be considered.
<0.01
When possible, patients with TEN should be managed in
a specialized intensive care unit or burn unit.
<0.01
(continued)
Table. Disagreement Indices for Each Proposed Item (continued)
Item
Disagreement
Indexa
There is no sufficient evidence to date that any specific
treatment aside from supportive care is beneficial for
patients with TEN.
<0.01
A complete blood count and comprehensive metabolic
panel is helpful in evaluating patients suspected of
having TEN.
0.40
Examination of all mucosal sites is essential for patients
suspected of having TEN.
<0.01
Evaluation for associated symptoms is essential for
patients suspected of having TEN.
0.19
The severity and risk of development of SJS and TEN
does not change with a leadin or slow titration period of
drugs highly associated with SJS and TEN.
0.95
Each factor calculated in the SCORTEN carries equal
prognostic weight.
0.65
It is helpful but not essential to obtain detailed
information on ethnicity in all patients suspected of
having SJS or TEN.
0.52
Patients with SJS and TEN frequently experience pruritus
of their skin at the start of disease.
0.97
Establishment of a diagnosis of SJS and TEN by a
dermatologist is essential.
0.37
The presence of lymphadenopathy is helpful in
evaluating a patient with TEN.
0.65
Assessing for viral reactivation (eg, herpes simplex
virus) is helpful in evaluating a patient with TEN.
0.53
Items the panel agreed were “inappropriate” regarding SJS/TEN
SJS and TEN are exclusively caused by drugs 0.75
A skin biopsy is required to establish a diagnosis of SJS
and TEN.
0.42
A skin biopsy for direct immunofluorescence is essential
in the evaluation of SJS and TEN.
0.72
Items the panel disagreed on regarding SJS/TEN
EMM, but not SJS/TEN, can be caused by infectious
triggers such as mycoplasma pneumoniae and Herpes
simplex.
1.04
Drugs administered for less than 2 days prior to the
onset of mucocutaneous physical findings are highly
unlikely to cause SJS and TEN.
1.27
A Nikolsky sign may be elicited on erythematous areas of
skin, but usually not on normal-appearing skin, in
patients with SJS and TEN.
1.70
There is no correlation between the extent of epidermal
detachment and mucosal membrane erosion severity in
SJS and TEN.
1.46
Skin lesions of SJS and TEN usually heal rapidly without
scar formation.
1.04
Factors calculated in the SCORTEN do not carry equal
prognostic weight.
1.01
Abbreviations: ACE, angiotensin-converting-enzyme; EM, erythema
multiforme; EMM, erythemamultiformemajor; NSAID, nonsteroidal
anti-inflammatory drug; OB/GYN, obstetrics and gynecology; SCORTEN,
severity-of-illness score for toxic epidermal necrolysis; SJS, Stevens-Johnson
syndrome; TEN, toxic epidermal necrolysis.
a A disagreement index value greater than 1 indicated a lack of consensus
among the participants in regards to the appropriateness of the statement.
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that did not make the final result include adding a more detailed
or complete HLA analysis and soliciting a baseline psychological
history. Expanding the HLA analysis was decided against because
of the low prevalence of other known mutations.
We have included various tools within the case report form
such as the SCORTEN. We have not included a specific causality
assessment tool because many different tools are available, but
none have been shown to be superior. As part of this NIH working
group, a future endeavor is to compare drug causality assessment
tools, such as the ALDEN (algorithm of drug causality for epider-
mal necrolysis) and Naranjo.25 Regardless of which tool is used, it
is important to document who completed the causality assess-
ment because the experience of the user can be a critical determi-
nant of reliability.
Conclusions
Wehavegenerated,with the consensusof experts fromaround the
world, a case report form that is the first of its kind thatwe knowof
for SJS/TEN.Wearehopeful that itwill help in standardizing thecol-
lection of patient information in future studies and in the reporting
of individual cases ofmarketed drugs, leading to improved charac-
terization andmanagement of SJS/TEN.
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NOTABLENOTES
Veit Stoss’s High Altar of StMary's Church—
A 15th Century Altar Depicting Skin Lesions
Andrzej Wincewicz, MD, PhD, FEBP
The wooden altarpiece at St. Mary’s Church in Cracow, Poland, is fa-
mous for its greatwealth of both carved andpainteddetaileddepiction
of the human body. Following themanner of Italianmasters, who exer-
cised their knowledge of human anatomy with great diligence, a cel-
ebrated German sculptor, Veit Stoss (circa 1450-1533), reproduced the
pathological skin lesions of hismodelswith great fidelity in the pentap-
tychof StMary’s Church (1477 to 1484) (a copyofVeit Stoss’sHighAltar
is kept in St John Cantius Church in Chicago).1
Themodels’ dermatological lesionswere identified by the rector of
JagiellonianUniversity,ProfessorFranciszekWalter (1885-1950).1 Forex-
ample, in theupperscene,called“thecaptureofChrist,”onthe inner right
panel of the closed altarpiece, there is a sharply defined, lenticular, de-
pressed lesion,which is consistentwith niche of ulcer, fromwhich an ir-
regularnodulearises in the skinover the right zygomaticboneof the sol-
dier in his 50s.1,2 As depicted on this typical, sun-exposed location on
thebody, this nodule is a classic imageof ulceratedbasal cell carcinoma
(carcinoma basocellulare exulcerans, ulcus rodens, basalioma).1,2 Next
to a soldier, the henchman holding a torch presents with an elongated,
pendulous excrescencehangingdown in themiddle of his neck, consis-
tentwith enormous benign fibroma pendulumor pedunculated soft fi-
broma(fibromamolluscum,fibromamolle).1,2Thethirdfigureofthesame
scene,aPharisee, isanexampleofclinicalpictureof latecongenital syphi-
lis (syphilis congenita tarda), characterized by the bald, square head of
a personwith congenital syphilis (caput quadratum), frontal tubers (tu-
bera frontalia) exophthalmus, convergent strabismus (strabismus con-
vergens), andanupturned “bulldognose.” In addition, ahallmarkof con-
genital lues, a similar saddle-like nose, belongs to a scholar in another
scene referred toas “Christ among thedoctorsor scholars” in themiddle
scene of the inner right wing of the closed altar.1,2 In a scene titled “De-
scent of Christ into hell” in the upper sceneof the outer left panel of the
closed altar, the face of Satan is depicted with symptoms of cutaneous
tuberculosis (lupusvulgaris vorax),withnodules andulcers onhis thick-
ened and distorted nose and on both cheeks. The complete destruc-
tion ofmodel’s upper lip, now replacedwith oblong vermilion ulcers, is
shown, as well as his exposed gums andmaxillary teeth revealing den-
tal caries and numerous defects.1,2 In “the resurrection of Christ” (up-
per scene of left panel of the opened altar), the sleeping soldier’s nose
is swollenandbluish redwithdilatedbloodvessels consistentwith acne
rosacea that could result inoutgrowthandsubsequentprotuberanceof
the nose (rhinophyma).1,3 Finally, in the central scene, “the Assump-
tion,” near the right edge of St Peter the Apostle’s nose there is a dark
wart, formerly called a senile wart (verruca senilis) and currently desig-
natedaspigmented seborrheic keratosis,which requiresdifferential di-
agnosis with melanocytic naevus.1,3
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1. Walter F. Veit Stoss: sculptor of skin diseases. Dermatological Details of St
Mary’s altar Wit Stwosz-rzeźbiarz chorób skórnych. Szczegóły dermatologiczne
ołtarza mariackiego. Cracow, Poland: Gebethner andWolff; 1933.
http://www.wbc.poznan.pl/dlibra/docmetadata?id=47328. Accessed February
28, 2017.
2. Closed Altar of St Mary Church in Cracow, Poland. High-resolution interactive
view. http://www.pajorama.eu/wirtualnymariacki/mariacki.html#/Oltarz_Wita
_Stwosza_zamkniety/. AccessedMarch 2, 2017.
3. Opened Altar of St Mary Church in Cracow, Poland. High-resolution
interactive view: http://www.pajorama.eu/wirtualnymariacki/mariacki.html#
/Oltarz_Wita_twosza_otwarty/. AccessedMarch 2, 2017.
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